Manias can occur in any market if enough people allow them to happen. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Normal trading activity in BOJA was disrupted by hurricanes Harvey and Irma, so I’d like a little more time for its improving fundamentals to get fully priced into the stock. Read More
There has been no news specific to FOXF to explain its sudden rise over the past three weeks, but I’ll happily take my 8% gain in less than two months. Read More
Stormy weather got September off to a rough start, but once the sun came out it was clear sailing. Read More
I am raising the stop price on FOXF to $42 to protect most of our profit since there has been no news to explain its rapid rise. Read More
Our Rapid Profits Matrix likes BHP from a short-term perspective due to its rapidly improving balance sheet. Read More
The solid rise in the S&P 500 over the first eight months of this year has given rise to the fallacy that the entire stock market is doing well in 2017. Um, not really. To be sure, on an equal-weight basis, the average stock in the index rose 8.6%… Read More
The rise in the S&P 500 over the first eight months of this year has given rise to a vulnerable, two-tiered market. Read More
It was only six weeks ago that I reiterated my confidence that Wells Fargo (NYSE: WFC) would fully recover from an embarrassing scandal triggered by the admission a year ago that bank employees had opened approximately 2 million bogus deposit and credit card accounts over several years to achieve ambitious… Read More
The stock dropped two weeks ago after the release of what appeared to be a fairly innocuous press release stating that its IDMC approved the continuation of its stage-3 trial. Read More